Literature DB >> 2896870

Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis.

C Babbs1, A Smith, L P Hunt, B P Rowan, N Y Haboubi, T W Warnes.   

Abstract

The prognostic value of the aminoterminal propeptide of type III procollagen (P3NP) was investigated in 63 patients with primary biliary cirrhosis (PBC) followed for up to 87 months. No patient with an initially normal serum P3NP level died during the study; survival was significantly worse with increasing serum P3NP levels. Cox multivariate analysis confirmed that serum P3NP was an independent prognostic variable. Positive correlations were found between serum P3NP and histological stage, pericellular fibrosis, piecemeal necrosis, and serum concentrations of alanine aminotransferase and aspartate aminotransferase. Raised P3NP levels also correlated with the degree of cholestasis as evaluated by serum bilirubin, serum alkaline phosphatase, and copper binding protein deposition in the liver. Serum P3NP is of prognostic value because it reflects the major pathophysiological features of PBC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896870     DOI: 10.1016/s0140-6736(88)91843-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Liver function tests.

Authors:  M F Laker
Journal:  BMJ       Date:  1990-08-04

2.  Localisation and semiquantitative assessment of hepatic procollagen mRNA in primary biliary cirrhosis.

Authors:  C J Goddard; A Smith; J A Hoyland; P Baird; R F McMahon; A J Freemont; M Shomaf; N Y Haboubi; T W Warnes
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

3.  Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.

Authors:  Rie Ouchi; Shodai Togo; Masaki Kimura; Tadahiro Shinozawa; Masaru Koido; Hiroyuki Koike; Wendy Thompson; Rebekah A Karns; Christopher N Mayhew; Patrick S McGrath; Heather A McCauley; Ran-Ran Zhang; Kyle Lewis; Shoyo Hakozaki; Autumn Ferguson; Norikazu Saiki; Yosuke Yoneyama; Ichiro Takeuchi; Yo Mabuchi; Chihiro Akazawa; Hiroshi Y Yoshikawa; James M Wells; Takanori Takebe
Journal:  Cell Metab       Date:  2019-05-30       Impact factor: 27.287

Review 4.  Liver transplantation and primary biliary cirrhosis.

Authors:  A K Burroughs; M Biagini; P A McCormick; K Rolles
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

5.  Referral of patients with primary biliary cirrhosis for liver transplantation.

Authors:  J M Neuberger; B K Gunson; J A Buckels; E Elias; P McMaster
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 6.  Non-invasive diagnosis of advanced fibrosis and cirrhosis.

Authors:  Suraj Sharma; Korosh Khalili; Geoffrey Christopher Nguyen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease.

Authors:  A Floreani; F Zappalà; M Mazzetto; R Naccarato; M Plebani; M Chiaramonte
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

Review 8.  Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact.

Authors:  Caterina Sagnelli; Salvatore Martini; Mariantonietta Pisaturo; Giuseppe Pasquale; Margherita Macera; Rosa Zampino; Nicola Coppola; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2015-10-28

9.  Predictive role of serum procollagen III peptide and Knodell's index in survival prognosis of patients with hepatitis B virus liver cirrhosis.

Authors:  Zarko Babić; Ante Bilić; Dobroslav Babić; Vjekoslav Jagić; Branko Nikolić; Martina Sunić
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

10.  Vitamin D deficiency: correlation to interleukin-17, interleukin-23 and PIIINP in hepatitis C virus genotype 4.

Authors:  Mona F Schaalan; Waleed A Mohamed; Hesham H Amin
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.